New York Attorney General Letitia James joined a bipartisan coalition of 47 other attorneys general in securing $17.85M from drug companies Bausch (BHC) and Lannett (LCI) for their role in “a massive, long-running scheme to inflate prices of generic drugs and reduce competition,” the AG announced. “The new settlements are part of an ongoing multistate litigation against dozens of companies for illegal agreements to fix prices for generic drugs. The companies in the scheme, some of which increased prices by 1,000 percent, manufactured essential medications to treat diseases ranging from diabetes to cancer to ADHD,” the AG stated.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BHC:
- Bausch’s RED-C miss raises pressure ahead of Xifaxan LOE, Truist says
- Midday Fly By: TikTok forms U.S. JV, Intel guidance underwhelms
- Bausch Health results from Phase 3 RED-C program did not meet primary endpoint
- Bausch Health price target raised to $8 from $7 at Truist
- Bausch Health initiated with an Equal Weight at Barclays